Compare

Propanc Biopharma, Inc. vs CytoDyn Inc. vs Tempest Therapeutics, Inc. vs Kala Bio, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearPropanc Biopharma, Inc.
PPCB
CytoDyn Inc.
CYDY
Tempest Therapeutics, Inc.
TPST
Kala Bio, Inc.
KALA
Year ended2026-06-302026-05-312025-12-312025-12-31
Revenuen/an/an/a$0
Revenue growth (YoY)n/an/an/an/a
Gross marginn/an/an/an/a
Operating marginn/an/an/an/a
Net marginn/an/an/an/a
Net income-$18.86M-$42.70M-$26.26M-$26.98M
EPS (Diluted)-$17.62-$0.03-$6.33-$3.31
Operating cash flow-$5.68M-$17.25M-$26.82M-$31.99M
Free cash flow-$5.69Mn/a-$26.82Mn/a
Cash & equivalentsn/a$11.85M$7.71M$7.56M
Total assets$12.78M$13.97M$16.93M$9.49M
Total liabilities$3.38M$123.69M$10.26M$2.49M
Shareholders' equity$9.40M-$109.72M$6.67M$7.00M
Return on year-end equity-200.6%n/a-393.9%-385.6%
Shares outstanding3.31M1.37B4.93M27.85M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearPropanc Biopharma, Inc.CytoDyn Inc.Tempest Therapeutics, Inc.Kala Bio, Inc.
Latestn/a$0
Ended 2023-05-31
$295.0K
Ended 2017-12-31
$0
Ended 2025-12-31
1 year earliern/a$266.0K
Ended 2022-05-31
$653.0K
Ended 2016-12-31
$0
Ended 2024-12-31
2 years earliern/a$0
Ended 2021-05-31
$277.0K
Ended 2015-12-31
$0
Ended 2023-12-31
3 years earliern/an/a$0
Ended 2014-12-31
$3.89M
Ended 2022-12-31
4 years earliern/an/a$0
Ended 2013-12-31
$11.24M
Ended 2021-12-31